January 7, 2025
BPGbio, Inc.‘s own president and CEO, Niven R Narain, Ph.D. gives his take on biopharma, AI and drug discovery in 2025 predictions for Bio-IT World.
From “Trendspotting: Predictions for Bio-IT World in 2025” by Bio-IT World Team:
“2025 will be a year of technology “truth-bombs” as the biopharma industry starts to see the realities with hyped AI drug discovery companies in the past five years: In 2025, sophisticated biopharma leaders will emphasize the importance of understanding patient biology upfront to AI, prioritizing patient-derived, longitudinal data over static, and siloed datasets. This paradigm shift will highlight AI’s role as an integrative tool, enhancing the drug development process rather than replacing it. Biology-first AI will be paramount in modeling complex systems like immune-tumor interactions, enabling smarter patient stratification, therapeutic combinations, and clinical trial designs…” – Niven R Narain, Ph.D., BPGbio, Inc.
For the complete take and numerous other fantastic insights from top industry experts and leaders, please check out the full piece here: Trendspotting: Predictions for Bio-IT World in 2025
About BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.
Media Contact:
media@bpgbio.com
